Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II study of oregovomab with PLD or weekly paclitaxel in PARP inhibitor-resistant ovarian, fallopian tube, or primary peritoneal cancer
KCT0007410Phase 2Completed
- Sponsor
- OncoQuest Inc.
- Start
- Jul 2022
- Modality
- DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of oregovomab, doxorubicin, paclitaxel in ovarian cancer, fallopian tube cancer (PFTC), primary peritoneal cancer (PPC), sponsored by OncoQuest Inc.. Started Jul 2022; status: completed.
02
Drugs
oregovomabdoxorubicinpaclitaxel
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on KCT0007410.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on KCT0007410.